Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGeisinger Health PlanGeisinger Health Plan Adcetris Coverage & Prior Au…
    Ask Trek AI about this page
    CurrentGeisinger Health PlanPolicy MBP 166.0

    Adcetris (brentuximab vedotin) medical benefit coverage

    Customize your policy alerts

    Sign up for Geisinger Health Plan Policy MBP 166.0 alerts

    Get alerted when Policy MBP 166.0 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity criteria and prior authorization requirements for Adcetris (brentuximab vedotin) for Geisinger Health Plan members across applicable lines of business. Affects providers prescribing or requesting coverage for Adcetris.

    Policy Summary
    PayerGeisinger Health Plan
    PolicyAdcetris (brentuximab vedotin) medical benefit coverage
    Policy CodePolicy MBP 166.0
    Change TypeNo material change
    Effective DateFeb 1, 2025
    Last ReviewNov 11, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization from the Medical Director or designee with documentation of diagnosis, prescriber specialty, age, planned combination therapy, and prior lines of therapy as required.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    all lines of businesspolicy applies to
    ≥18minimum age
    prior authauthorization requirement
    ≥2 prior linesLBCL prior therapy

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    6 monthstypical initial approval

    Medical Necessity & Coverage Criteria

    Medical Necessity Criteria by Indication

    Covered when ALL of the following are met:

    General authorization: Prior Authorization by Medical Director or Designee required; prescription written by a hematologist/oncologist

    Grandfather provision: members already on therapy may be approved with documentation of FDA approval or adequate evidence

    Classical Hodgkin Lymphoma (cHL) - indication options

    • Post-auto-HSCT relapse: Patient at least 18 years of age AND medical record documentation of failure of autologous hematopoietic stem cell transplant (auto-HSCT)
    • Failure of ≥2 chemo regimens: Patient at least 18 years of age AND medical record documentation of failure of at least 2 multi-agent chemotherapy regimens and patient is not a candidate for auto-HSCT
    • Consolidation post-auto-HSCT: Patient at least 18 years of age AND medical record documentation of use as consolidation treatment following auto-HSCT in high-risk patients (refractory to first line, relapse within 12 months, or extranodal disease)
    • Previously untreated advanced cHL (adult): Patient at least 18 years of age AND medical record documentation of previously untreated Stage III or IV cHL AND documentation that Adcetris will be used in combination with doxorubicin, vinblastine, and dacarbazine
    • Previously untreated high-risk cHL (pediatric): Patient at least 2 years of age AND medical record documentation of previously untreated high-risk cHL AND documentation that Adcetris will be used in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide
    Systemic Anaplastic Large Cell Lymphoma (sALCL): Prescription written by a hematologist/oncologist; patient at least 18 years of age; medical record documentation of sALCL meeting one of the following: failure of at least 1 prior multi-agent chemotherapy regimen OR previously untreated sALCL when Adcetris will be used in combination with cyclophosphamide, doxorubicin, and prednisone

    Document prior regimen failure or planned combination use

    Primary Cutaneous ALCL or CD30-expressing MF: Prescription written by a hematologist/oncologist; patient at least 18 years of age; diagnosis of primary cutaneous ALCL or CD30-expressing mycosis fungoides AND medical record documentation of failure of prior radiation or systemic therapy
    Peripheral T-cell Lymphomas (PTCL): Prescription written by a hematologist/oncologist; patient at least 18 years of age; diagnosis of CD30-expressing PTCL (including angioimmunoblastic T-cell lymphoma and PTCL NOS) AND documentation that Adcetris will be used in combination with cyclophosphamide, doxorubicin, and prednisone
    Relapsed or Refractory Large B-Cell Lymphoma (LBCL): Prescription written by a hematologist/oncologist; patient at least 18 years of age; diagnosis of relapsed or refractory LBCL (including DLBCL NOS, DLBCL arising from indolent lymphoma, or HGBL); documentation that Adcetris will be used in combination with lenalidomide and a rituximab product; documentation of two or more prior lines of systemic therapy; and documentation that patient is not eligible for autologous HSCT or CAR T-cell therapy

    Peripheral T-cell Lymphomas (PTCL)

    Covered when ALL of the following are met for Peripheral T-cell Lymphomas (PTCL):

    PTCL coverage criteria: Prescription written by a hematologist/oncologist; patient at least 18 years of age; medical record documentation of a diagnosis of a CD30-expressing peripheral T-cell lymphoma (including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified); and documentation that Adcetris will be used in combination with cyclophosphamide, doxorubicin, and prednisone.

    Relapsed or Refractory LBCL

    Covered when ALL of the following are met for Relapsed or Refractory Large B-Cell Lymphoma (LBCL):

    LBCL coverage criteria: Prescription written by a hematologist/oncologist; patient at least 18 years of age; medical record documentation of a diagnosis of relapsed or refractory LBCL (including DLBCL NOS, DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma); documentation that Adcetris will be used in combination with lenalidomide and a rituximab product; documentation of two or more prior lines of systemic therapy; and documentation that the patient is not eligible for autologous HSCT or CAR T-cell therapy.

    This section does not list any explicit exclusions. The policy states that Adcetris (brentuximab vedotin) will be considered medically necessary when all listed criteria are met and includes a grandfather provision for members already established on therapy, but it does not enumerate specific exclusionary conditions in the coverage criteria portion of the document.

    Coverage and any line-of-business specific benefit limitations or exclusions are governed by eligibility and contract terms for each line of business. Coverage statements in the applicable line-of-business benefit document supersede this policy, so providers should consult the member's benefit plan for any additional restrictions before requesting authorization.

    Within the coverage criteria section itself there are no explicit statements labeling particular uses as “not medically necessary”. The policy defines the conditions under which Adcetris is considered medically necessary but does not provide discrete not-medically-necessary language in this portion of the document.

    Coverage for Adcetris will be discontinued if the member experiences unacceptable toxicity or worsening of disease. Authorization durations for relapsed indications are typically limited (for example, initial approvals of up to 6 months), and subsequent approvals require documentation of continued disease improvement or lack of progression; therapy must be stopped when toxicity or disease worsening occurs.

    Initial Therapy Requirements

    Initial Therapy Requirements

    Initial therapy coverage conditions are indication-specific and often require prior therapy failure or specified combination regimens.

    General: Prescription must be written by a hematologist/oncologist and medical records must document diagnosis, age, prior therapies or planned combination regimen as specified per indication

    Relapsed or Refractory LBCL initial therapy

    LBCL initial therapy requirements: Prescription written by a hematologist/oncologist; patient at least 18 years of age; diagnosis of relapsed or refractory LBCL; planned combination with lenalidomide and a rituximab product; documentation of two or more prior systemic therapy lines; and documentation that the patient is not eligible for autologous HSCT or CAR T-cell therapy.

    Prior Authorization & Documentation Requirements

    Prior Authorization

    Prior authorization required; grandfathering allowed

    Prior authorization is required and must be obtained from the Medical Director or designee before Adcetris will be approved. Members already established on Adcetris may be grandfathered if the medical record documents that safety and effectiveness for the prescribed indication are supported by FDA approval or adequate medical/scientific evidence.

    • Grandfather provision: members already established on therapy are eligible for approval with supporting FDA or medical literature documentation.
    Prior Authorization

    Prior authorization — required documentation

    Submit prior authorization requests that include documentation of the member’s diagnosis, the prescribing provider’s specialty (hematologist/oncologist), patient age, planned combination therapy (when applicable), and prior lines of therapy or transplant/CAR T eligibility status as specified by indication.

    • Diagnosis documented in the medical record.
    • Prescriber is a hematologist/oncologist.

    Continuation, Grandfathering & Authorization Durations

    Continuation/Grandfathering

    Grandfather provision for members already established on therapy.

    Grandfathered members: Members already established on Adcetris are eligible for approval if the medical record documents safety and effectiveness supported by FDA approval or adequate medical/scientific evidence.

    Requires documentation

    Continuation and authorization duration rules

    Authorization durations and requirements for subsequent approvals vary by indication and require documentation of benefit or literature support for extension:

    Previously untreated stage III/IV cHL continuation: Initial approval limited to 12 doses (6 months); continuation beyond initial 12 doses requires documentation of well-controlled, peer-reviewed literature to support further treatment.12 doses

    Step Therapy / Prior Treatment Table

    Document / EvidenceWhat must be in the medical record
    Diagnosis documentation
    Medical record showing the specific diagnosis (e.g., cHL, sALCL, pcALCL, PTCL, LBCL) and patient age as required by the indication (age ≥18 for most adult indications; age ≥2 for previously untreated high‑risk pediatric cHL)
    Required prior therapies or statusDocumentation required to demonstrate failure or ineligibility
    Relapsed or refractory LBCL: ≥2 prior systemic therapy lines
    Medical record documentation listing the two or more prior lines of systemic therapy (regimens and dates) and clinical evidence of progression or nonresponse to those therapies
    Ineligibility for auto‑HSCT or CAR T‑cell therapy (LBCL)
    Medical record explanation why patient is not eligible for autologous HSCT or CAR T‑cell therapy (e.g., comorbidities, prior transplant failure, organ dysfunction), with treating hematologist/oncologist statement documenting ineligibility
    Failure of autologous HSCT (cHL-specific)
    Medical record documenting prior auto‑HSCT and subsequent relapse or progression after transplant
    Failure of ≥2 multi‑agent chemotherapy regimens (cHL-specific, transplant-ineligible)
    Medical record documenting the specific multi‑agent regimens tried and evidence of treatment failure or intolerance, and statement that patient is not a candidate for auto‑HSCT
    Failure of prior radiation or systemic therapy (pcALCL / CD30‑expressing MF)
    Medical record documenting prior radiation and/or systemic therapy and documentation of failure or intolerance

    Site-of-Care & Benefit Limitations

    Billing Rule

    Site‑of‑care: check line‑of‑business and contract limits for infusion center

    Line‑of‑business benefit documents may define site‑of‑care limitations; check eligibility and contract‑specific benefit limitations for infusion center coverage and any site‑of‑care restrictions.

    • Verify line‑of‑business benefit document for site‑of‑care limitations.
    • Eligibility and contract specific limits may apply to infusion center coverage.

    Key Definitions

    Adcetris (brentuximab vedotin)
    CompositionThree-component antibody–drug conjugate: a CD30-specific chimeric IgG1 antibody (cAC10), the cytotoxic agent monomethylauristatin E (MMAE), and a protease‑cleavable dipeptide linker that covalently conjugates MMAE to cAC10.
    TargetBinds to cells expressing CD30 via the cAC10 antibody component.
    Mechanism of actionAfter binding CD30 the conjugate is internalized and releases MMAE, which disrupts microtubules, induces G2/M cell cycle arrest, and triggers apoptosis.
    Drug classAntibody–drug conjugate (ADC).
    Medical Necessity — definition
    DefinitionMedical Necessity: Covered services rendered by a health care provider that the Plan determines are appropriate for the symptoms and diagnosis or treatment, provided for direct care, consistent with current standards of good medical treatment, not primarily for convenience, and the most appropriate level of service.

    Background

    Adcetris (brentuximab vedotin) is an antibody–drug conjugate composed of a CD30-targeting monoclonal antibody linked to the cytotoxic agent monomethyl auristatin E (MMAE). After binding CD30 on tumor cells, the conjugate is internalized and a protease-cleavable linker releases MMAE intracellularly. MMAE disrupts microtubule dynamics causing G2/M cell-cycle arrest and apoptosis, providing targeted cytotoxicity against CD30-expressing lymphomas.

    Policy Summary
    PayerGeisinger Health Plan
    PolicyAdcetris (brentuximab vedotin) medical benefit coverage
    Policy CodePolicy MBP 166.0
    Change TypeNo material change
    Effective DateFeb 1, 2025
    Last ReviewNov 11, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization from the Medical Director or designee with documentation of diagnosis, prescriber specialty, age, planned combination therapy, and prior lines of therapy as required.
    SourceLink
    On This Page
    Medical Necessity & Coverage CriteriaInitial Therapy RequirementsPrior Authorization & Documentation RequirementsContinuation, Grandfathering & Authorization DurationsStep Therapy / Prior Treatment TableSite-of-Care & Benefit LimitationsKey DefinitionsBackground
  1. Patient age documented (adult indications generally ≥18 years).
  2. Planned combination regimen (e.g., with CHOP, lenalidomide plus rituximab, or specific pediatric combinations).
  3. Prior lines of systemic therapy and eligibility for auto‑HSCT or CAR T when required.
  4. Step Therapy

    Required prior therapy — document prior regimen failure or ineligibility

    Coverage is contingent on medical record documentation of prior therapy failure or ineligibility per indication (e.g., failure of autologous HSCT, failure of ≥2 multi‑agent chemotherapy regimens, failure of prior radiation or systemic therapy, or other specified prior regimen failures).

    • Document failure of auto‑HSCT when claimed for post‑transplant relapse.
    • Document failure of at least two multi‑agent chemotherapy regimens when required.
    • Document failure of prior radiation or systemic therapy for pcALCL or CD30‑expressing MF.
    • If claiming ineligibility for transplant/CAR T, include documentation supporting ineligibility.
    • For sALCL, document failure of ≥1 prior multi‑agent regimen when applicable.
    Step Therapy

    Relapsed/refractory LBCL — prior therapies and ineligibility required

    For relapsed or refractory LBCL, prior authorization requires documentation of two or more prior lines of systemic therapy and that the patient is not eligible for autologous HSCT or CAR T‑cell therapy.

    • Prescription must be written by a hematologist/oncologist.
    • Medical record documentation of ≥2 prior systemic therapy lines for LBCL.
    • Documentation that the patient is not eligible for auto‑HSCT or CAR T‑cell therapy.
    Documentation Required

    Required medical record documentation

    Medical records submitted with the prior authorization must support the diagnosis, patient age, prior therapies or transplant status, and the specific combination regimens or reasons for transplant/CAR T ineligibility as specified by indication.

    • Clear documentation of diagnosis tied to the specific covered indication.
    • Patient age documented (most adult indications require ≥18 years).
    • Prior therapy history or transplant/CAR T status and reasons for ineligibility.
    • Planned or prior combination regimens documented (e.g., lenalidomide + rituximab; CHOP).
    Documentation Required

    Additional documentation specifics (diagnosis, age, prescriber, CD30)

    Include indication‑specific supporting details: diagnosis consistent with the listed indication, patient age (≥18 for adult indications; pediatric criteria where specified), prescribing hematologist/oncologist, and CD30 expression documentation where required.

    • Confirm CD30 expression documentation for indications that require it (e.g., CD30‑expressing PTCL).
    • Document prescriber specialty as hematologist/oncologist.
    • Document patient age and that it meets the age requirement for the indication.
    Denial Risk

    Denial risk for lack of prior authorization

    Requests submitted without prior authorization from the Medical Director or designee may be denied; prior authorization must be obtained and supported by the required documentation meeting policy criteria.

    • Obtain prior authorization prior to initiating therapy unless member is grandfathered with required documentation.
    Denial Risk

    Coverage discontinuation and Medicaid note

    Therapy must be discontinued and will no longer be covered if the member experiences unacceptable toxicity or worsening of disease; Medicaid (GHP Family) requests that do not meet PARP criteria will be evaluated case‑by‑case.

    • Discontinue Adcetris for unacceptable toxicity or disease progression.
    • Medicaid (GHP Family) exceptions evaluated on a case‑by‑case basis.
    Previously untreated high-risk pediatric cHL continuation: Initial approval limited to 5 doses (15 weeks); continuation beyond initial 5 doses requires documentation of well-controlled, peer-reviewed literature.5 doses
    Previously untreated sALCL/other CD30 PTCL continuation: Initial approval limited to 8 doses (6 months); continuation beyond initial 8 doses requires supporting peer-reviewed literature.8 doses
    Relapsed pcALCL/CD30-expressing MF/consolidation: Initial approvals typically limited to 6 months; subsequent approval may allow one additional 6-month authorization to reach up to 16 cycles; further treatment past 16 cycles requires supporting literature.16 cycles
    Relapsed cHL and relapsed/refractory LBCL continuations: Initial approval typically 6 months; subsequent approvals up to 12 months require documentation of continued disease improvement or lack of progression; therapy discontinued if unacceptable toxicity or disease worsening occurs.6 months
    Application to hospitalizationWhen applied to hospitalization, member requires acute inpatient care that cannot be safely provided as an outpatient.
    ExclusionsServices primarily for convenience are not medically necessary.
    CD30‑expressing peripheral T‑cell lymphoma (PTCL)
    ScopeCD30‑expressing peripheral T‑cell lymphomas (PTCL) for adult patients (≥18 years).
    Included diagnosesIncludes angioimmunoblastic T‑cell lymphoma and peripheral T‑cell lymphoma not otherwise specified (PTCL NOS).
    Prescriber requirementPrescription must be written by a hematologist/oncologist and documented in the medical record.
    Planned regimenAdcetris must be used in combination with cyclophosphamide, doxorubicin, and prednisone for covered PTCL use.
    Relapsed or refractory Large B‑Cell Lymphoma (LBCL)
    ScopeRelapsed or refractory Large B‑Cell Lymphoma (LBCL) in adults (≥18 years).
    Included subtypesIncludes diffuse large B‑cell lymphoma (DLBCL) Not Otherwise Specified (NOS), DLBCL arising from indolent lymphoma, and high‑grade B‑cell lymphoma (HGBL).
    Prior therapy requirementMedical record documentation of two (2) or more prior lines of systemic therapy is required.
    Eligibility for transplant/CAR TPatient must be documented as not eligible for autologous HSCT or CAR T‑cell therapy.
    Planned regimenAdcetris must be used in combination with lenalidomide and a rituximab product for covered LBCL use.